Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 76Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Burkitt Lymphoma 16Recurrence 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Neoplasms, Plasma Cell 5Lymphoma 5Leukemia, Biphenotypic, Acute 5Immunoglobulin Light-chain Amyloidosis 5Smoldering Multiple Myeloma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Leukemia 4Neoplasm Metastasis 3Down Syndrome 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Prostatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Lung Neoplasms 2Leukemia, Hairy Cell 2Hodgkin Disease 2Fatigue 2Brain Neoplasms 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2

Interventions

Dexamethasone 3daratumumab 2Lenalidomide 2pomalidomide 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1dexamethasone acetate 1dexamethasone 21-phosphate 1cc-486 1carfilzomib 1auricularum 1Specimen Handling 1Radiotherapy 1Immunotherapy, Adoptive 1Calcium Dobesilate 1Bortezomib 1Biopsy 12-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Plasmacytoma × Calcium Dobesilate × 1 year × Clear all
NCT03031730 2026-02-10

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Terminated
35 enrolled 10 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡